Bronchodilators are central to the management of chronic obstructive pulmonary disease
(COPD). Clinical studies combining different classes of bronchodilators, in particular a long …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Bronchodilators provide improvements in lung function and reductions in symptoms and
exacerbations, and are the mainstay of pharmacological management of chronic obstructive …

When there are no randomised clinical trials directly comparing all relevant treatment
options, an indirect treatment comparison via meta-analysis of the available clinical …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Objective: This study aimed to quantitatively compare the efficacy and safety of long-acting
β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations …

Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …

Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and
mortality. COPD is typified by persistent, progressive airflow limitation and a range of …

Recently, the results of an interesting systematic review have shown that the use of a
combination of a longacting b2-agonist (LABA) and a long-acting antimuscarinic agent …

Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …